Document is current
Any future updates will be listed below
-
Authors
Hammarlund, Emma U. https://orcid.org/0000-0001-7625-4793
Amend, Sarah R. https://orcid.org/0000-0002-5606-1262
Pienta, Kenneth J. https://orcid.org/0000-0002-4138-2186
-
Funding
Funding for this research was provided by:
Vetenskapsrådet (2019-05254)
H2020 Marie Skłodowska-Curie Actions (690817)
Prostate Cancer Foundation
National Cancer Institute (U54CA143803)
National Cancer Institute (CA163124)
National Cancer Institute (CA093900)
National Cancer Institute (CA143055)
Patrick C. Walsh Prostate Cancer Research Fund
- License Information
-
More Information
Article History
Received: 23 April 2020
Accepted: 3 June 2020
First Online: 13 June 2020
Compliance with ethical standards
:
: KJP is a consultant and hold stocks for Cue Biopharma, Inc., Greenmark Biomedical, Inc., MEDSYN Biopharma, LLC, and Oncopia Therapeutics. LLC. KJP is a consultant for Akrevia Therapeutics, Inc., GloriousMed, Inc, Arkray, Inc., and Clinomics, Inc. KJP receives research funding from Progenics, Inc.
